Cargando…
Comparison of Outcomes between 3 Monthly Brolucizumab and Aflibercept Injections for Polypoidal Choroidal Vasculopathy
We compared the short-term outcomes between 3-monthly aflibercept and brolucizumab injections for treatment-naïve polypoidal choroidal vasculopathy (PCV). A total of 52 eyes were included. Patients received 3 monthly intravitreal aflibercept (n = 38) or intravitreal brolucizumab (n = 14). Indocyanin...
Autores principales: | , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8469297/ https://www.ncbi.nlm.nih.gov/pubmed/34572350 http://dx.doi.org/10.3390/biomedicines9091164 |
_version_ | 1784573894846316544 |
---|---|
author | Fukuda, Yoshiko Sakurada, Yoichi Matsubara, Mio Hasebe, Yuka Sugiyama, Atsushi Kikushima, Wataru Kashiwagi, Kenji |
author_facet | Fukuda, Yoshiko Sakurada, Yoichi Matsubara, Mio Hasebe, Yuka Sugiyama, Atsushi Kikushima, Wataru Kashiwagi, Kenji |
author_sort | Fukuda, Yoshiko |
collection | PubMed |
description | We compared the short-term outcomes between 3-monthly aflibercept and brolucizumab injections for treatment-naïve polypoidal choroidal vasculopathy (PCV). A total of 52 eyes were included. Patients received 3 monthly intravitreal aflibercept (n = 38) or intravitreal brolucizumab (n = 14). Indocyanine green angiography (ICGA) was performed at baseline and at the 3-month visit. Selection of anti-VEGF agents depended on time. In the brolucizumab-treated group, best-corrected visual acuity (BCVA) improved from 0.27 ± 0.34 (log MAR unit) at baseline to 0.20 ± 0.24 at 3-month visit, which is comparable with the aflibercept-treated group (p = 0.87), after adjustment of confounding factors. Central retinal thickness significantly decreased by 43%−44% in both groups. Subfoveal choroidal thickness also significantly decreased by 20.5% during this interval in the brolucizumab-treated group, which was greater than the aflibercept-treated group. The complete resolution rate of polypoidal lesions on ICGA was significantly higher (p = 0.043) in the brolucizumab-treated group (78.6%) than in the aflibercept-treated group (42.1%). Intraocular inflammation was observed in 14.3% (2/14) in the brolucizumab-treated group only. In short-term follow-up, intravitreal injection of 3-monthly brolucizumab was comparable with aflibercept in terms of BCVA and morphological improvement along with higher resolution of polypoidal lesion(s) on ICGA. |
format | Online Article Text |
id | pubmed-8469297 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-84692972021-09-27 Comparison of Outcomes between 3 Monthly Brolucizumab and Aflibercept Injections for Polypoidal Choroidal Vasculopathy Fukuda, Yoshiko Sakurada, Yoichi Matsubara, Mio Hasebe, Yuka Sugiyama, Atsushi Kikushima, Wataru Kashiwagi, Kenji Biomedicines Article We compared the short-term outcomes between 3-monthly aflibercept and brolucizumab injections for treatment-naïve polypoidal choroidal vasculopathy (PCV). A total of 52 eyes were included. Patients received 3 monthly intravitreal aflibercept (n = 38) or intravitreal brolucizumab (n = 14). Indocyanine green angiography (ICGA) was performed at baseline and at the 3-month visit. Selection of anti-VEGF agents depended on time. In the brolucizumab-treated group, best-corrected visual acuity (BCVA) improved from 0.27 ± 0.34 (log MAR unit) at baseline to 0.20 ± 0.24 at 3-month visit, which is comparable with the aflibercept-treated group (p = 0.87), after adjustment of confounding factors. Central retinal thickness significantly decreased by 43%−44% in both groups. Subfoveal choroidal thickness also significantly decreased by 20.5% during this interval in the brolucizumab-treated group, which was greater than the aflibercept-treated group. The complete resolution rate of polypoidal lesions on ICGA was significantly higher (p = 0.043) in the brolucizumab-treated group (78.6%) than in the aflibercept-treated group (42.1%). Intraocular inflammation was observed in 14.3% (2/14) in the brolucizumab-treated group only. In short-term follow-up, intravitreal injection of 3-monthly brolucizumab was comparable with aflibercept in terms of BCVA and morphological improvement along with higher resolution of polypoidal lesion(s) on ICGA. MDPI 2021-09-05 /pmc/articles/PMC8469297/ /pubmed/34572350 http://dx.doi.org/10.3390/biomedicines9091164 Text en © 2021 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Article Fukuda, Yoshiko Sakurada, Yoichi Matsubara, Mio Hasebe, Yuka Sugiyama, Atsushi Kikushima, Wataru Kashiwagi, Kenji Comparison of Outcomes between 3 Monthly Brolucizumab and Aflibercept Injections for Polypoidal Choroidal Vasculopathy |
title | Comparison of Outcomes between 3 Monthly Brolucizumab and Aflibercept Injections for Polypoidal Choroidal Vasculopathy |
title_full | Comparison of Outcomes between 3 Monthly Brolucizumab and Aflibercept Injections for Polypoidal Choroidal Vasculopathy |
title_fullStr | Comparison of Outcomes between 3 Monthly Brolucizumab and Aflibercept Injections for Polypoidal Choroidal Vasculopathy |
title_full_unstemmed | Comparison of Outcomes between 3 Monthly Brolucizumab and Aflibercept Injections for Polypoidal Choroidal Vasculopathy |
title_short | Comparison of Outcomes between 3 Monthly Brolucizumab and Aflibercept Injections for Polypoidal Choroidal Vasculopathy |
title_sort | comparison of outcomes between 3 monthly brolucizumab and aflibercept injections for polypoidal choroidal vasculopathy |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8469297/ https://www.ncbi.nlm.nih.gov/pubmed/34572350 http://dx.doi.org/10.3390/biomedicines9091164 |
work_keys_str_mv | AT fukudayoshiko comparisonofoutcomesbetween3monthlybrolucizumabandafliberceptinjectionsforpolypoidalchoroidalvasculopathy AT sakuradayoichi comparisonofoutcomesbetween3monthlybrolucizumabandafliberceptinjectionsforpolypoidalchoroidalvasculopathy AT matsubaramio comparisonofoutcomesbetween3monthlybrolucizumabandafliberceptinjectionsforpolypoidalchoroidalvasculopathy AT hasebeyuka comparisonofoutcomesbetween3monthlybrolucizumabandafliberceptinjectionsforpolypoidalchoroidalvasculopathy AT sugiyamaatsushi comparisonofoutcomesbetween3monthlybrolucizumabandafliberceptinjectionsforpolypoidalchoroidalvasculopathy AT kikushimawataru comparisonofoutcomesbetween3monthlybrolucizumabandafliberceptinjectionsforpolypoidalchoroidalvasculopathy AT kashiwagikenji comparisonofoutcomesbetween3monthlybrolucizumabandafliberceptinjectionsforpolypoidalchoroidalvasculopathy |